Protocol Title: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

Target Population: Limited-Stage Small Cell Lung Cancer

Summary: To determine whether administering High-Dose Thoracic Radiotherapy, 70 Gy (2 Gy once-daily over 7 Weeks) or 61.2 Gy (1.8 Gy once-daily for 16 Days followed by 1.8 Gy twice-daily for 9 Days), will improve Median and 2-Year Survival compared with 45 Gy (1.5 Gy twice-daily over 3 Weeks) in patients with Limited Stage Small Cell Lung Cancer.

Key Inclusion Criteria:
- Documentation of Disease:
  - Histologically or cytologically documented Small Cell Lung Cancer (SCLC).
  - Limited-Stage Disease patients with disease restricted to 1 Hemithorax with regional Lymph Node Metastases, including Ipsilateral Hilar, Ipsilateral and Contralateral Mediastinal, and Ipsilateral Supraclavicular Lymph Nodes.
    - Patients with disease involvement of the Contralateral Hilar or Supraclavicular Lymph Nodes are NOT eligible.
    - Patients with Pleural Effusions that are visible on plain chest radiographs, whether cytologically positive or not are NOT eligible unless they have a negative Thoracentesis.
    - Patients with cytologically positive Pleural or Pericardial Fluid are NOT eligible.
- Measurable disease.
- Prior Treatment:
  - Patients may have received only 1 cycle of chemotherapy prior to enrolling on CALGB 30610, which must have included Carboplatin or Cisplatin and Etoposide.
  - If a patient has had 1 cycle of Cisplatin or Carboplatin / Etoposide prior to registration, the patient must have had all of it prior to registration tests as outlined in the protocol and prior to starting their first cycle of chemotherapy.
  - Additionally, these patients also must have met all of the eligibility criteria in the protocol prior to receiving the first cycle of chemotherapy.
  - Registration to CALGB 30610 must take place within 14-21 Days after the start of the non-protocol therapy.
  - No prior radiotherapy or chemotherapy (except for the chemotherapy described above) for SCLC.
  - No prior Mediastinal or Thoracic Radiotherapy.
  - Patients with complete surgical resection of disease are NOT eligible.

Contacts:
- Principal Investigator: Suma Satti, MD
- Research Nurses (RN): Nicole Duffaut (nicole.duffaut@ochsner.org, ext. 23683)
  Melanie Breaux (mbreaux@ochsner.org, ext. 24478)

For additional information: https://clinicaltrials.gov/ct2/show/study/NCT00632853

IRB# 2010.172 N